A5047115795- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- Immunotherapy and Immune Responses
- Bladder and Urothelial Cancer Treatments
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Virus-based gene therapy research
- Advanced Breast Cancer Therapies
- Nonmelanoma Skin Cancer Studies
- Ferroptosis and cancer prognosis
- Urinary and Genital Oncology Studies
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Multiple and Secondary Primary Cancers
- Cutaneous lymphoproliferative disorders research
- Cancer Research and Treatments
- Brain Metastases and Treatment
- Renal and related cancers
- Viral Infectious Diseases and Gene Expression in Insects
- Computational Drug Discovery Methods
- Cell Adhesion Molecules Research
- Esophageal Cancer Research and Treatment
- Immune Cell Function and Interaction
Peking University Cancer Hospital
2016-2025
Peking University
2016-2025
Chongqing Medical and Pharmaceutical College
2025
Army Medical University
2016-2022
Ministry of Education
2021-2022
Xinqiao Hospital
2022
Seventh People's Hospital of Shanghai
2020
Beijing Institute of Education
2011
Peking Union Medical College Hospital
2011
Chinese Academy of Medical Sciences & Peking Union Medical College
2008-2011
Metastatic mucosal melanoma responds poorly to anti-programmed cell death-1 (PD-1) monotherapy. Vascular endothelial growth factor (VEGF) has been shown play an important immunosuppressive role in the tumor microenvironment. The combination of VEGF inhibition and PD-1 blockade provides therapeutic opportunities for patients refractory either therapy alone.We conducted a single-center, phase IB trial evaluating safety preliminary efficacy toripalimab, humanized immunoglobulin G4 monoclonal...
Abstract Purpose: Programmed cell death receptor-1 (PD-1) inhibitors are frontline therapy in advanced melanoma. Severe immune-related adverse effects (irAEs) often require immunosuppressive treatment with glucocorticoids (GCCs), but GCC use and its correlation patient survival outcomes during anti–PD-1 monotherapy remains unclear. Experimental Design: In this multicenter retrospective analysis, patients treated between 2009 2019 detailed use, data were identified from five independent...
Mucosal melanoma is rare and associated with extremely poor prognosis. However, standard adjuvant therapy for mucosal has not been established. We conducted a randomized phase II clinical trial in patients resected to compare the efficacy safety of high-dose IFN-α2b (HDI) temozolomide-based chemotherapy as therapy.Patients stage II/III after surgery were into three groups: observation group (group A, alone), HDI B, treated 15 × 10(6) U/m(2)/d IFN-α2b, followed by 9 U IFN-α2b), temozolomide...
JS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies. This phase I study is designed to evaluate safety, tolerability, clinical activity JS001 advanced melanoma or urologic cancer patients who are refractory standard systemic therapy. In dose escalation cohorts, subjects initially received single-dose, intravenous infusion were followed for 28 days by...
Purpose: Effective therapies for the majority of metastatic acral melanoma patients have not been established. Thus, we investigated genetic aberrations CDK4 pathway in and evaluated efficacy CDK4/6 inhibitors targeted therapy melanoma.Experimental Design: A total 514 primary samples were examined copy number variations (CNV) pathway-related genes, including Cdk4, Ccnd1, P16INK4a , by QuantiGenePlex DNA Assay. The sensitivity established cell lines patient-derived xenograft (PDX) containing...
PD-1 checkpoint blockade immunotherapy induces long and durable response in patients with advanced melanoma. However, only a subset of melanoma benefit from this approach. The mechanism triggering the innate resistance anti-PD-1 therapy remains unclear.Experimental Design: Whole-exome sequencing (WES) RNA (RNA-Seq) analyses were performed training cohort (n = 31) using baseline tumor biopsies treated antibody. Copy-number variations (CNVs) for genes CDK4, CCND1, CDKN2A assayed TaqMan...
Programmed cell death receptor-1 (PD-1) monotherapy is a standard treatment for advanced cutaneous melanoma, but its efficacy and toxicity are defined in white populations remain poorly characterized other ethnic groups, such as East Asian, Hispanic African.To determine the of PD-1 different groups.Clinical data patients with unresectable or melanoma treated anti-PD-1 between 2009 2019 were collected retrospectively from five independent institutions USA, Australia China. Tumour response,...
Mucosal melanoma is an aggressive subtype with poor response to antiprogrammed cell death-1 (PD-1) monotherapy. Axitinib in combination toripalimab, a humanized IgG4 mAb against PD-1, showed promising rate patients metastatic mucosal (MM) phase Ib study. Here, we report the updated overall survival (OS), duration of (DoR), and biomarker analysis results.Patients advanced MM received toripalimab 1 or 3 mg/kg intravenously every 2 weeks combined axitinib 5 mg orally two times per day until...
Background OH2 is an oncolytic virus derived from herpes simplex type 2. A phase Ia/Ib clinical trial in China was conducted patients with unresected stage III–IV melanoma, the majority of whom had acral type, to assess safety and preliminary efficacy OH2. Methods The enrolled histologically confirmed unresectable III or advanced IV melanoma. In Ia, nine received single-dose treatment across three dose levels (10 6 , 10 7 8 CCID 50 /mL, where represents cell culture infectious 50%) while six...
657 Background: SHR-A2102 is a novel ADC that consists of fully humanized IgG1 monoclonal antibody targeting nectin-4, cleavable linker, and topoisomerase I inhibitor payload with high membrane permeability potent cell-killing efficacy. We have initiated first-in-human phase 1 study to assess the safety, tolerability, efficacy in advanced solid tumors. Here, we present preliminary findings, focusing on urothelial carcinoma. Methods: Patients (pts) locally unresectable or metastatic...
Purpose: Ethnic differences are conspicuous in melanoma. This study is to obtain a comprehensive view of genomic landscape and better understanding the correlations gene mutation status with clinicopathologic characteristics disease prognosis Asian population.Experimental Design: A total 2,793 melanoma patient samples were retrospectively collected analyzed for mutations C-KIT, BRAF, NRAS, PDGFRA coding regions telomerase reverse transcriptase (TERT) promoter region by Sanger sequencing....
Mucosal melanoma (MM) is a highly vascularized tumor with an extremely poor prognosis. In this randomized, open-label, phase II study, we characterized the efficacy and safety of bevacizumab in combination carboplatin plus paclitaxel (CPB) patients previously untreated advanced MM.Patients were randomly assigned 2:1 ratio to receive (area under curve, 5) (175 mg/m2) once every 4 weeks (CPB arm, 5 mg/kg) or without (CP arm) 2 weeks. Progression-free survival (PFS) was primary end point....
515 Background: RC48-ADC is a novel humanized anti-HER2 antibody-drug conjugate (ADC), which showed promising data in HER2-positive and even negative patients (pts) with metastatic urothelial carcinoma (mUC). Toripalimab an anti-PD-1 antibody durable antitumor effect for mUC. The combination may have synergistic effect. Initial RC48-C014 was previously presented (ASCO 2021); here we reported update on safety ORR. Methods: In dose-escalation cohort, pts received 1.5 or 2 mg/kg + 3mg/kg...
Background Melanoma in people of Asian descent presents primarily non-sun-exposed areas, such as acral and mucosal melanoma. Compared with the predominant sun-exposed area melanomas Caucasians, do not respond well to immunotherapy are associated a worse prognosis. Hence, there is an urgent need for improved treatment melanoma Asians. This phase Ib trial evaluated safety efficacy modified herpes simplex virus-1 oncolytic virus OrienX010 Chinese patients unresectable stage IIIC–IV Methods...
Acral melanoma, known for low tumor mutation burden, responds poorly to immunotherapy. A standard therapy is still lacking.
<h3>Background/objective</h3> In patients with conjunctival melanomas, surgery is the first choice of treatment, but no standard adjuvant therapy has been established. this study, we evaluated prognostic factors for melanoma in ethnic Chinese patients. <h3>Methods</h3> Demographic data, known (published) factors, BRAF and KIT gene mutations, treatment strategies outcomes were reviewed 53 pathologically confirmed melanomas. Univariate multivariate analyses associated survival performed by...
Abstract Background The clinicopathological and survival profiles across primary sites in acral melanoma (AM) are still controversial unclear. Methods This is a multi-center retrospective study. Clinicopathological data of AM patients diagnosed between 1 January 2000 31 December 2017 from 6 large tertiary hospitals China were extracted. Chi square tests used to compare basic characteristics sole, palm nail bed. Melanoma-specific (MSS) differences based on compared by log-rank multivariate...
4519 Background: RC48-ADC is a novel humanized anti-HER2 antibody-drug conjugate (ADC). A phase II clinical study showed that has good effect on locally advanced or metastatic urothelial carcinoma with HER2-positive expression failed standard chemotherapy. In the study, some patients HER2-postive immunohistochemistry (IHC 2+) but negative FISH test still benefited from treatment of RC48-ADC.This was to evaluate activity and safety in HER2-negative carcinoma. Methods: This an open-label,...
The frequency of HER2 overexpression in bladder cancer is reported as 9%-61%. alteration correlates with aggressive disease cancer. Traditional anti-HER2 targeted therapy has failed to show clinical benefits patients advanced urothelial carcinoma .The information on pathologically proven detected status was collected from the database Peking University Cancer Hospital. expression, well its association characteristics and prognosis, analyzed.A total 284 consecutive were enrolled. positive...
4566 Background: Disitamab vedotin has shown promising data across a spectrum of HER2 expression in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who progressed on chemotherapy. This study was conducted to evaluate the safety and efficacy disitamab plus anti-PD-1 antibody carcinoma. Methods: is an open-label, multicenter, phase 1b/2 trial activity RC48-ADC combined toripalimab, humanized immunoglobin G 4 monoclonal against PD-1 mUC. Patients received at 1.5 2...